ArticleBMC cancer2026

Metastasis-directed SBRT for oligometastatic hormone sensitive prostate cancer (METRO): protocol for a prospective randomised phase III trial, NCT04983095.

Karin Söderkvist et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.